Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Shipo Wu; Jianying Huang; Zhe Zhang; Jianyuan Wu; Jinlong Zhang; Hanning Hu; Tao Zhu; Jun Zhang; Lin Luo; Pengfei Fan; Busen Wang; Chang Chen; Yi Chen; Xiaohong Song; Yu Wang; Weixue Si; Tianjian Sun; Xinghuan Wang; Lihua Hou; Wei Chen

doi:10.1016/s1473-3099(21)00396-0

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Shipo Wu(Academy of Military Medical Sciences), Jianying Huang(Zhongnan Hospital of Wuhan University), Zhe Zhang(Academy of Military Medical Sciences), Jianyuan Wu(Zhongnan Hospital of Wuhan University), Jinlong Zhang(Academy of Military Medical Sciences), Hanning Hu(Wuhan University), Tao Zhu(CanSino (China)), Jun Zhang(Academy of Military Medical Sciences), Lin Luo(Zhongnan Hospital of Wuhan University), Pengfei Fan(Academy of Military Medical Sciences), Busen Wang(Academy of Military Medical Sciences), Chang Chen(Zhongnan Hospital of Wuhan University), Yi Chen(Academy of Military Medical Sciences), Xiaohong Song(Academy of Military Medical Sciences), Yu Wang(Academy of Military Medical Sciences), Weixue Si(CanSino (China)), Tianjian Sun, Xinghuan Wang(Zhongnan Hospital of Wuhan University), Lihua Hou(Academy of Military Medical Sciences), Wei Chen(Academy of Military Medical Sciences)

The Lancet Infectious Diseases

July 26, 2021

10.1016/s1473-3099(21)00396-0

Cited by 300Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis